Source:http://linkedlifedata.com/resource/pubmed/id/10708936
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-4-20
|
| pubmed:abstractText |
The aim of this study was to evaluate the prognostic value of p53 nuclear accumulation and Bcl-2 expression after curative surgery for rectal cancer. Immunohistochemistry was performed using monoclonal antibodies (MAb) (DO-1 for p53; anti-human Bcl-2 MAb, clone 124, for Bcl-2) on formalin-fixed, paraffin-embedded tissues of 160 rectal carcinomas (UICC stages I-III), and results were compared with data from the prospective registry of rectal cancer by univariate and multivariate logistic regression model focusing specifically on recurrence. Survival was calculated by the Kaplan-Meier method and proportional hazards model. p53 nuclear accumulation was documented in 39% (n=63) of tumours and was associated with a higher incidence of tumour progression (local or distant recurrence) and poorer disease-free survival (P<0.0001). Bcl-2 expression was detected in 29% (n=47), and was associated with longer disease-free survival and lower incidence of recurrence (P<0.0086). Multivariate logistic regression analysis demonstrated that gender (P=0.0136), UICC stage (P=0.0002), p53 expression (P=0.0002) and Bcl-2 expression (P=0. 0243) were independent factors predictive of recurrence. The proportional hazards model identified p53 (P=0.0009), UICC stage (P=0.0480), gender (P=0.0049), but not Bcl-2 (P=0.1503), as independently related to disease-free survival. Looking at the p53/Bcl-2 subgroups, the poorest prognosis was observed in the p53+/Bcl-2- subgroup, whereas patients whose tumours were p53-/Bcl-2+ had the best prognosis (P<0.0001). Immunohistochemical assessment of both p53 and Bcl-2 status may be valuable in predicting recurrence and survival after curative surgery for rectal cancer. Therefore, they play a role as prognostic factors in rectal cancer. p53 is a stronger predictor of prognosis than Bcl-2.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0959-8049
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
36
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
348-56
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10708936-Adult,
pubmed-meshheading:10708936-Aged,
pubmed-meshheading:10708936-Aged, 80 and over,
pubmed-meshheading:10708936-Disease-Free Survival,
pubmed-meshheading:10708936-Female,
pubmed-meshheading:10708936-Follow-Up Studies,
pubmed-meshheading:10708936-Humans,
pubmed-meshheading:10708936-Immunohistochemistry,
pubmed-meshheading:10708936-Logistic Models,
pubmed-meshheading:10708936-Male,
pubmed-meshheading:10708936-Middle Aged,
pubmed-meshheading:10708936-Neoplasm Proteins,
pubmed-meshheading:10708936-Neoplasm Recurrence, Local,
pubmed-meshheading:10708936-Neoplasm Staging,
pubmed-meshheading:10708936-Prognosis,
pubmed-meshheading:10708936-Proportional Hazards Models,
pubmed-meshheading:10708936-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:10708936-Rectal Neoplasms,
pubmed-meshheading:10708936-Sex Factors,
pubmed-meshheading:10708936-Tumor Suppressor Protein p53
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer.
|
| pubmed:affiliation |
Department of Surgery, Medical University of Luebeck, Ratzeburger Allee 160, D-23538, Luebeck, Germany. ao.schwandner@t-online.de
|
| pubmed:publicationType |
Journal Article
|